The Life Sciences team represented Base Therapeutics in the out-licensing of its proprietary base editing technology on a non-exclusive basis to a leading international biopharmaceutical company last year for development in certain fields. Pursuant to the relevant agreement, Base Therapeutics would receive eight-figure upfront payment and research and development milestone payments.
Base Therapeutics has developed a high-fidelity base editor that is highly efficient with no off-target-editing effect.
The Goodwin team was led by Can Cui, who is also leading the Goodwin team advising multiple Chinese gene editing companies in intellectual property matters and cross-border license and collaboration transactions.
For more details, read the article (in Chinese) in Wenhui Bao, a Chinese daily newspaper published by the Shanghai United Media Group.